Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04778592 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain

A Phase 2 study of Lumbosacral Radiculopathy, sponsored by Eliem Therapeutics (UK).

Completed
Registry status
Phase 2
Development phase
149
Enrollment target
20
Study locations

NCT04778592 is a Phase 2 study of Lumbosacral Radiculopathy that has completed, run by Eliem Therapeutics (UK). The registered enrollment target is 149 participants, above the 30-participant average among 3 other Lumbosacral Radiculopathy trials with a reported enrollment target (397% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04778592, a Phase 2 study of Lumbosacral Radiculopathy, has completed, sponsored by Eliem Therapeutics (UK).

COMPLETED
Registry status
Phase 2
Development phase
149 participants
Enrollment target
20
Study locations

Study Summary

Efficacy and Safety of ETX 018810 in Subjects with Lumbosacral Radicular Pain

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG ETX-018810

Study Locations (20)

Florida

  • Charter Research - Lady Lake
  • Cordova Research Institute - Miami
  • Advanced Medical Research Institute - Miami
  • Coral Research Clinic Corp - Miami

Georgia

  • Drug Studies America - Marietta
  • Better Health Clinical Research - Newnan

New York

  • Drug Trials America - Hartsdale
  • University of Rochester Translational Pain Research - Rochester

Alabama

  • Delta Clinical Research - Mobile

Arizona

  • Arizona Research Center - Phoenix

Colorado

  • DBPS Research LLC - Greenwood Village

Idaho

  • Injury Care Research - Boise

Illinois

  • Chicago Anesthesia Research Specialist - Chicago

Trial Details

FieldValue
Enrollment Target 149 participants
Start Date 2021-01-19
Est. Completion 2022-05-25
Phase Phase 2

Sponsor

Eliem Therapeutics (UK)

2 total trials

What the Registry Record Tells You About NCT04778592

The ClinicalTrials.gov registry entry for NCT04778592 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 30-participant average among 3 other Lumbosacral Radiculopathy trials with a reported enrollment target (397% higher). The listed sponsor is Eliem Therapeutics (UK), which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lumbosacral Radiculopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04778592 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Georgia, New York.

Frequently Asked Questions

What is clinical trial NCT04778592 about?

NCT04778592 is a clinical study titled "Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain". Efficacy and Safety of ETX 018810 in Subjects with Lumbosacral Radicular Pain

What is the current status of trial NCT04778592?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2021-01-19. Estimated completion is 2022-05-25.

What conditions does trial NCT04778592 study?

This clinical trial studies the following conditions: Lumbosacral Radiculopathy.

What interventions are being tested in trial NCT04778592?

The interventions under investigation include: Placebo (DRUG), ETX-018810 (DRUG).

Who is sponsoring clinical trial NCT04778592?

This trial is sponsored by Eliem Therapeutics (UK), which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04778592 being conducted?

This trial has 20 study locations across Alabama, Arizona, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lumbosacral Radiculopathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.